A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 | Zendy

Natàlia Casamitjana | Zendy; Marc Corbacho-Monné | Zendy; María Ubals | Zendy; Andrea Alemany | Zendy; Clara Suñer | Zendy; Cristian Tebé | Zendy; Aurelio Tobı́as | Zendy; Judith Peñafiel | Zendy; Ester Ballana | Zendy; Carla A. Pérez | Zendy; Pol Admella | Zendy; Nuria Martí | Zendy; Pep Laporte | Zendy; Jordi Mitjà | Zendy; Mireia Clua | Zendy; Laia Bertran | Zendy; Maria Sarquella | Zendy; Sergi Gavilán | Zendy; Jordi Ara | Zendy; Josep M. Argimón | Zendy; Gabriel Cuatrecasas | Zendy; M. Paz Cañadas | Zendy; Aleix ElizaldeTorrent | Zendy; Robert Fabregat | Zendy; Magı́ Farré | Zendy; Anna Forcada | Zendy; Gemma FloresMateo | Zendy; Cristina López | Zendy; Esteve Muntada | Zendy; Núria Nadal | Zendy; Silvia Narejos | Zendy; Aroa Nieto | Zendy; Núria Prat | Zendy; Jordi Puig | Zendy; Carles Quiñones | Zendy; Ferran Ramírez-Viaplana | Zendy; Juliana ReyesUrueña | Zendy; Eva RiveiraMuñoz | Zendy; Lı́dia Ruiz | Zendy; Sergi Sanz | Zendy; Alexis Sentís | Zendy; Alba Sierra | Zendy; César Velasco | Zendy; Rosa Maria VivancoHidalgo | Zendy; Juani Zamora | Zendy; Jordi Casabona | Zendy; Martí Vall-Mayans | Zendy; Camila González-Beiras | Zendy; Bonaventura Clotet | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19

Author(s) -

Natàlia Casamitjana,

Marc Corbacho-Monné,

María Ubals,

Andrea Alemany,

Clara Suñer,

Cristian Tebé,

Aurelio Tobı́as,

Judith Peñafiel,

Ester Ballana,

Carla A. Pérez,

Pol Admella,

Nuria Martí,

Pep Laporte,

Jordi Mitjà,

Mireia Clua,

Laia Bertran,

Maria Sarquella,

Sergi Gavilán,

Jordi Ara,

Josep M. Argimón,

Gabriel Cuatrecasas,

M. Paz Cañadas,

Aleix ElizaldeTorrent,

Robert Fabregat,

Magı́ Farré,

Anna Forcada,

Gemma FloresMateo,

Cristina López,

Esteve Muntada,

Núria Nadal,

Silvia Narejos,

Aroa Nieto,

Núria Prat,

Jordi Puig,

Carles Quiñones,

Ferran Ramírez-Viaplana,

Juliana ReyesUrueña,

Eva RiveiraMuñoz,

Lı́dia Ruiz,

Sergi Sanz,

Alexis Sentís,

Alba Sierra,

César Velasco,

Rosa Maria VivancoHidalgo,

Juani Zamora,

Jordi Casabona,

Martí Vall-Mayans,

Camila González-Beiras,

Bonaventura Clotet

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2021801

Subject(s) - hydroxychloroquine , medicine , asymptomatic , incidence (geometry) , confidence interval , randomized controlled trial , adverse effect , covid-19 , coronavirus , disease , infectious disease (medical specialty) , physics , optics

Current strategies for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are limited to nonpharmacologic interventions. Hydroxychloroquine has been proposed as a postexposure therapy to prevent coronavirus disease 2019 (Covid-19), but definitive evidence is lacking.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research